225 related articles for article (PubMed ID: 18163212)
21. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
[TBL] [Abstract][Full Text] [Related]
22. [CLINICAL, BIOCHEMICAL AND HORMONAL PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ACROMEGALY].
Mykytyuk MR
Lik Sprava; 2015; (5-6):34-40. PubMed ID: 27089713
[TBL] [Abstract][Full Text] [Related]
23. Carpal tunnel syndrome and acromegaly.
Baum H; Lüdecke DK; Herrmann HD
Acta Neurochir (Wien); 1986; 83(1-2):54-5. PubMed ID: 3799250
[TBL] [Abstract][Full Text] [Related]
24. Acromegaly: a review of current medical therapy and new drugs on the horizon.
Fleseriu M; Delashaw JB; Cook DM
Neurosurg Focus; 2010 Oct; 29(4):E15. PubMed ID: 20887125
[TBL] [Abstract][Full Text] [Related]
25. The GH-IGF-I axis and the cardiovascular system: clinical implications.
Colao A
Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
[TBL] [Abstract][Full Text] [Related]
26. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
27. 5 Long-term acromegaly and associated cardiovascular complications: a case-based review.
Colao A
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S31-8. PubMed ID: 20129192
[TBL] [Abstract][Full Text] [Related]
28. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
30. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
31. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
32. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.
Holdaway IM; Bolland MJ; Gamble GD
Eur J Endocrinol; 2008 Aug; 159(2):89-95. PubMed ID: 18524797
[TBL] [Abstract][Full Text] [Related]
33. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.
Gadelha MR; Kasuki L; Lim DST; Fleseriu M
Endocr Rev; 2019 Feb; 40(1):268-332. PubMed ID: 30184064
[TBL] [Abstract][Full Text] [Related]
34. [Acromegaly and pregnancy: report of six new cases].
Persechini ML; Gennero I; Grunenwald S; Vezzosi D; Bennet A; Caron P
J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):704-12. PubMed ID: 24035359
[TBL] [Abstract][Full Text] [Related]
35. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
37. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
38. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
39. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors.
Ho PJ; Jaffe CA; Friberg RD; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 1994 Jun; 78(6):1403-10. PubMed ID: 7911124
[TBL] [Abstract][Full Text] [Related]
40. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
